H-CYTE (OTCMKTS:HCYTD) & Assure (OTCMKTS:IONM) Critical Comparison

Risk & Volatility

Assure has a beta of 217.15, indicating that its stock price is 21,615% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Assure and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assure	N/A	N/A	N/A
H-CYTE	-450.40%	N/A	-777.68%

Institutional & Insider Ownership

3.3% of Assure shares are owned by institutional investors. 3.8% of Assure shares are owned by insiders. Comparatively, 5.2% of H-CYTE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Assure and H-CYTE”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assure	$250,000.00	0.01	-$26.08 million	($56.12)	0.00
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has higher revenue and earnings than Assure.

About Assure

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.